Enlivex Therapeutics Ltd (ENLV) Stock Analysis

Enlivex Therapeutics Ltd (ENLV) is a publicly traded company in the HEALTHCARE sector. It trades at $0.86, carries a market capitalization of $208.12M, a price-to-earnings ratio of 0.03. This page summarizes the public market data, fundamentals, and frequently asked questions for ENLV, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Enlivex Therapeutics Ltd currently has a Bullish sentiment score of 0.41.

About Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd. is a clinical-stage biopharmaceutical company headquartered in Nes Ziona, Israel, specializing in the development of innovative immunotherapeutic solutions through its proprietary Alum-based platform designed to modulate the immune system. The company focuses on addressing critical conditions, including cancer and autoimmune disorders, by harnessing its unique technologies to improve therapeutic outcomes. With a promising pipeline and a dedication to advancing immune...

GNG Research Analysis

GNG Research scores Enlivex Therapeutics Ltd (ENLV) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ENLV.

Frequently Asked Questions

Does ENLV pay dividends?

Enlivex Therapeutics Ltd (ENLV) does not currently pay a regular dividend.

What is ENLV's P/E ratio?

Enlivex Therapeutics Ltd has a price-to-earnings (P/E) ratio of 0.03.

What is ENLV's market cap?

Enlivex Therapeutics Ltd (ENLV) has a market capitalization of $208.12M with a current stock price of $0.86.